During Wednesday’s current trade, Pfizer Inc (NYSE:PFE)’s shares picked up 0.39%, and is now trading at $34.67, after Merck KGaA, Darmstadt, Germany, and Pfizer Inc., New York, US, declared the finalization of the co-promotion contract allowing the companies to co-promote Pfizer’s anaplastic lymphoma kinase (ALK) inhibitor XALKORI® (crizotinib). This contract showcases the alliance’s commitment to establishing a combined oncology sales organization in key markets in advance of the potential launch of avelumab*-based treatment regimens in the future.
XALKORI is the first ALK inhibitor approved in the United States, Japan and the European Union (EU) and is supported by two positive global randomized trials in the first- and second-line ALK-positive advanced non-small cell lung cancer (NSCLC) treatment settings. To date, globally more than 8,000 patients have been treated with XALKORI, counting those who received XALKORI in clinical trials.
In 2015, Merck KGaA, Darmstadt, Germany, will receive a reimbursement associated with its promotion of XALKORI, followed by an 80 percent (Pfizer), 20 percent (Merck KGaA, Darmstadt, Germany) profit sharing on the product starting in 2016. The co-promotion term will last through December 31, 2020 for the United States, Canada, Japan, France, Germany, Italy, Spain and the United Kingdom, and from January 1, 2016 through December 31, 2021 in China and Turkey. Pfizer will report the sales of XALKORI in countries where it is co-promoted with Merck KGaA, Darmstadt, Germany.
“We are proud and excited to share the legacy of XALKORI, a medicine that changed the treatment paradigm for patients with ALK-positive metastatic NSCLC, with Merck KGaA, Darmstadt, Germany,” said Liz Barrett, president and general manager, Pfizer Oncology. “Through our co-promotion of XALKORI, we will establish a best-in-class global sales organization that will be exceptionally prepared for the potential launches of our future oncology medicines.”
Pfizer Inc., a biopharmaceutical corporation, discovers, develops, manufactures, and sells healthcare products worldwide. The corporation operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops, registers, and commercializes medicines for various therapeutic areas, counting inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases, and women’s/men’s health.
AT&T Inc (NYSE:T)’s shares dipped -0.02% during the current trading session Wednesday’s, and is now trading at $32.67, as AT&T Inc ( T), has invested more than $875 million in its best-in-class wireless and wired networks in South Carolina between 2012 and 2014, driving a wide range of upgrades to reliability, coverage, speed and performance for residents and business customers.
As part of its Project Velocity IP (VIP), an investment plan focused on network enhancement and expansion, AT&T in 2014 made 289 network upgrades in South Carolina, counting new cell sites, addition of wireless and wired network capacity, and new broadband network connections.
“With a growing range of connected home appliances, cars and wearable devices, we depend more on network connectivity than ever before,” said AT&T South Carolina President Pamela Lackey. “Announcements like this are why it is imperative that South Carolina continually evaluate and update our rules and policies to ensure that we are encouraging investments in the technologies that provide the tools our citizens and businesses need for success in a global economy.”
Notable South Carolina network enhancements in 2014 comprised of:
- 63 new cell sites;
- 183 network connection upgrades; and
- 43 new capacity upgrades.
“Infrastructure of all kinds is essential to economic development,” said South Carolina Secretary of Commerce Bobby Hitt. “Private investment, particularly in advanced communication technology, is one of the engines that will drive our state’s economic growth and assist create jobs.”
AT&T provides the nation’s most reliable 4G LTE network recently, covering more than 300 million Americans with 4G LTE service.** AT&T’s network also has the nation’s strongest LTE signal.***
AT&T Inc. provides telecommunications services in the United States and internationally. The corporation operates through two segments, Wireless and Wireline. The Wireless segment offers data and voice services, counting local, long-distance, and network access services, in addition to roaming services to youth, family, professionals, small businesses, government, and business customers.
Mylan NV (NASDAQ:MYL), during its Wednesday’s current trading session enhanced 13.40%, and is now trading at $67.26.
Today, Mylan NV (MYL), declared that Mylan has made a proposal to attain Perrigo Corporation plc (PRGO) in a cash-and-stock transaction that would create a diversified, global pharmaceutical leader with an unmatched commercial and operating platform and a unique, one-of-a-kind profile. The combination of these highly complementary businesses would produce a corporation with critical mass in specialty brands, generics, over-the-counter (OTC) and nutritional products; a powerful commercial platform with reach across all customer channels; an exceptional high-quality operating platform; and opportunities to generate improved growth and deliver noteworthy immediate and long-term value and benefits for shareholders and the other stakeholders of both companies.
Under the terms of the non-binding proposal, which was delivered to Perrigo’s Chairman on April 6, 2015, Perrigo shareholders would receive $205 in a combination of cash and Mylan stock for each Perrigo share, which represents a greater than 25% premium to the Perrigo trading price as of the close of business on Friday, April 3, 2015 (the last trading date preceding to the date of Mylan’s proposal), a greater than 29% premium to Perrigo’s sixty-day average share price and a greater than 28% premium to Perrigo’s ninety-day average share price.
Mylan N.V., through its auxiliaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The corporation provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, or transdermal patch forms, in addition to active pharmaceutical ingredients (APIs).
General Electric Corporation (NYSE:GE)’s shares declined -0.14% during the current trading session Wednesday’s, and is now trading at $24.99, as GE Antares, a unit of GE Capital, declared it is serving as administrative agent on a $138 million senior secured credit facility to support the attainment of Bendon, Inc. by Irving Place Capital (IPC). GE Capital Markets served as joint lead arranger and joint book runner on this facility.
Established in 2002 and headquartered in Ashland, OH, Bendon is a leading provider of non-licensed and licensed children’s coloring and activity products. Bendon sells products such as coloring and activity books, kits, sets and play packs, puzzles and other early childhood development games.
“GE Antares’ willingness to underwrite the full commitment and their large hold position made them an excellent financing partner on this transaction,” said John Howard, CEO at IPC. “We continue to benefit from our relationships with the GE Antares team.”
General Electric Corporation (GE) operates as an infrastructure and financial services corporation worldwide. The corporation’s Power and Water segment offers gas, steam and aero derivative turbines, nuclear reactors, generators, combined cycle systems, controls, and related services; wind turbines; and water treatment services and equipment. Its Oil and Gas segment provides surface and subsea drilling and production systems, equipment for floating production platforms, compressors, turbines, turbo expanders, reactors, industrial power generation, and auxiliary equipment.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
